Reshape Lifesciences Inc Quick Ratio (RSLS) starting from the first quarter 2026 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Reshape Lifesciences Inc  (NASDAQ: RSLS)

Reshape Lifesciences Inc's Quick Ratio

RSLS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Reshape Lifesciences Inc's Cash & cash equivalent grew by 54.12 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Reshape Lifesciences Inc's Quick Ratio to 4.1, above Reshape Lifesciences Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 202 other companies have achieved higher Quick Ratio than Reshape Lifesciences Inc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 734, from total ranking in the third quarter 2025 at 1011.

Explain Quick Ratio?
How much Cash & cash equivalents RSLS´s has?
What are RSLS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RSLS Quick Ratio (Mar 31 2026)
Q1		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -62.73 % -22.51 % 7.36 % 17.16 % 17.64 %
Y / Y Cash & cash equivalent Change 8531.78 % 668.1 % 3095 % 5.72 % -97.71 %
Quick Ratio MRQ 4.1 1.83 0.15 0.61 0.02
RSLS's Total Ranking # 734 # 1011 # 1281 # 1654 #
Seq. Current Liabilities Change -31.25 % 19.98 % -36.95 % -28.33 % 42.92 %
Seq. Cash & cash equivalent Change 54.12 % 1388.53 % -84.76 % 2368.11 % -86.29 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 203
Healthcare Sector # 332
Overall Market # 734


Quick Ratio Statistics
High Average Low
9.35 1.92 0.04
(Dec 31 2010)   (Mar 31 2021)




Financial Statements
Reshape Lifesciences Inc's Current Liabilities $ 2 Millions Visit RSLS's Balance sheet
Reshape Lifesciences Inc's Cash & cash equivalent $ 9 Millions Visit RSLS's Balance sheet
Source of RSLS's Sales Visit RSLS's Sales by Geography


Cumulative Reshape Lifesciences Inc's Quick Ratio

RSLS's Quick Ratio for the trailling 12 Months

RSLS Quick Ratio

 (Mar 31 2026)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -23.75 % 4.97 % 7.85 % -5.56 % -26.43 %
Y / Y Cash & cash equivalent TTM Growth 437.75 % 14.68 % -54.89 % -73.77 % -83.37 %
Quick Ratio TTM 1.45 0.56 0.23 0.21 0.21
Total Ranking TTM # 3784 # 2925 # 3197 # 2705 #
Seq. Current Liabilities TTM Growth -23.14 % -5.49 % 1.09 % 3.84 % 5.81 %
Seq. Cash & cash equivalent TTM Growth 99.85 % 132.61 % 11.01 % 4.2 % -57.38 %

Quick ratio ranking by company, industry and sector >> Back to RSLS Financial Strength Comparisons >> Go to Compare RSLS Quick Ratio to its Competitors

On the trailing twelve months basis RSLS Cash & cash equivalent more than doubled by 8531.78 % in Q1 2026 year on year, while Current Liabilities plummeted to $2 millions, this led to increase in in Reshape Lifesciences Inc's Quick Ratio to 1.45, above RSLS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 426 other companies have achieved higher Quick Ratio than Reshape Lifesciences Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 2925 to 3784.

Explain Quick Ratio?
How much Cash & cash equivalents RSLS´s has?
What are RSLS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 427
Healthcare Sector # 867
Within the Market # 3784


trailing twelve months Quick Ratio Statistics
High Average Low
3.45 1.24 0.12
(Sep 30 2017)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Pmv Pharmaceuticals Inc   11.27 $ 93.549  Millions$ 8.302  Millions
Whitehawk Therapeutics Inc   11.13 $ 123.043  Millions$ 11.056  Millions
Olema Pharmaceuticals Inc   10.94 $ 505.347  Millions$ 46.211  Millions
Wave Life Sciences Ltd   10.93 $ 544.591  Millions$ 49.831  Millions
Avalyn Pharma Inc   10.92 $ 123.127  Millions$ 11.280  Millions
Ovid Therapeutics Inc   10.88 $ 155.522  Millions$ 14.289  Millions
Abcellera Biologics Inc   10.81 $ 427.669  Millions$ 39.551  Millions
Enveric Biosciences Inc   10.66 $ 4.909  Millions$ 0.461  Millions
Ideaya Biosciences Inc   10.41 $ 671.201  Millions$ 64.481  Millions
Immuneering Corporation  10.37 $ 47.322  Millions$ 4.561  Millions
Synlogic Inc   10.35 $ 14.105  Millions$ 1.363  Millions
Spero Therapeutics Inc   10.23 $ 56.129  Millions$ 5.489  Millions
Cytomx Therapeutics Inc   10.19 $ 346.707  Millions$ 34.023  Millions
Revelation Biosciences Inc   9.96 $ 14.113  Millions$ 1.417  Millions
Nektar Therapeutics  9.85 $ 568.604  Millions$ 57.708  Millions
Lipocine Inc   9.78 $ 24.729  Millions$ 2.528  Millions
Boundless Bio Inc   9.69 $ 92.847  Millions$ 9.583  Millions
Promis Neurosciences inc   9.65 $ 63.848  Millions$ 6.615  Millions
Newamsterdam Pharma Company N v   9.54 $ 636.105  Millions$ 66.696  Millions
Silo Pharma Inc  9.53 $ 6.032  Millions$ 0.633  Millions
Kailera Therapeutics Inc   9.47 $ 519.174  Millions$ 54.836  Millions
Erasca Inc   9.14 $ 243.788  Millions$ 26.664  Millions
Anixa Biosciences Inc   9.12 $ 13.686  Millions$ 1.501  Millions
Diamedica Therapeutics Inc   9.11 $ 51.331  Millions$ 5.633  Millions
Acrivon Therapeutics Inc   8.84 $ 97.737  Millions$ 11.054  Millions
Medicinova Inc   8.83 $ 27.329  Millions$ 3.096  Millions
Neuphoria Therapeutics Inc   8.81 $ 13.327  Millions$ 1.513  Millions
Milestone Pharmaceuticals Inc   8.80 $ 184.216  Millions$ 20.944  Millions
Nuvation Bio Inc   8.74 $ 533.729  Millions$ 61.089  Millions
Spyre Therapeutics Inc   8.71 $ 741.467  Millions$ 85.162  Millions

Date modified: 2026-09-26T07:30:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.